Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't believe it is.
El Sohly and his group have been doing research for 40 years as you know. Nemus went through their pipeline and selected the ones they thought had the combo of being the most valuable and fastest to market. Nemus has first rights to anything else.
I believe El Sohly and his staff interact with Brian several times a week and Brian goes down there frequently. They are paid for any additional research needed but it's a heck of a lot cheaper than having to contract it out. Plus they're incentivized long term. It's another built in advantage as I'd estimate it has saved Nemus a couple million dollars over the last 3 years.
Unreal. I wonder why nobody has tried to get FDA approval for a smokeable cannabis drug? Oh, because it would have no chance of getting approved.
They won't be ready to start trials on their EB drug for at least a year and more likely 18 months. Glaucoma is out further than that. Any news would come from Bioinformatics or Biosynthesis if they have value.
Long term, they could develop something of value and the price will go up if they execute. That being said, this is why paid pumps piss me off. A few idiots were on here defiending it but it's unethical. All the people who bought in at artificially inflated prices got screwed.
Why did they announce filing a provisional glaucoma patent in 2015 and then again in 2017? What happened to the one in 2015?
They had a licensing deal with another company maybe 7 or 8 years ago that didn't perform on the milestones so the deal was terminated.
The suppository is just the fastest and cheapest way to get approval which has value. It's also strategic and a means to an end.
There are 3 categories. Recreational, medicinal, and FDA approved cannabinoids. Once FDA approved drugs hit the market, they're going to put a lot of pressure on the medicinal sector. It will also be the only cannabis related drugs doctors will prescribe and insurance will cover. It will be dramatically cheaper than medicinal. It will come down to how effective the drugs are. If they're as effective, it's going to be tough to justify having medical marijuana that's not as safe and pure as FDA approved drugs. And the market will shift to the most cost effective versions as well.
There's also going to be some push back on the availability of marijuana down the road. It's not nearly as safe as people think with the THC levels there are now. It's going to take a while for word to get out but emergency room doctors in Colorado and other states are seeing multiple cannabis related psychosis cases daily. About 20% of the population has a genetic predisposition to developing psychosis with regular pot use. Those who have an episode, will develop schizophrenia with continued use. The information on this is in its infancy but there's a group of moms across the country who are banding together after their kids developed problems or killed themselves. As the numbers come in and more people are impacted, it's going to be moms and doctors who lead the backlash on this. I'm sure this sounds crazy but just watch what happens and google the studies done in Europe on this. Look up the AKT-1 gene and cannabis psychosis to see the research that's been done so far.
Also, reports coming out of Colorado are that transplant patients who use marijuana are having much higher rejection rates than those who don't. They think it's related to cannabinoids blocking enzymes in the liver. We're going to see more side effects we had no idea were there.
Now, the genie is clearly out of the bottle and there's huge money backing legalizing marijuana and it's currently in favor with the media and politicians, but that can change when we see serious unintended consequences and pharma has safe alternatives on the market.
Catalent is the top company in the world for this. Nemus should be able to fast track this drug saving considerable time and money and will get a development deal done or will be bought out.
I think there's a short window for producers of medical marijuana. 3-5 years. Some may do very well during that time but then there's going to be a showdown once pharma puts out FDA approved cannabinoids and I don't see how pharma loses.
Yes he has. Thats why all drugs being developed bypass the liver.
Little known fact that he knew, 2 drug companies and I forget which ones, were in Phase III clinical trials with oral cannabinoids and pulled the plug due to adverse psychological effects. Happened in the late 90's I believe. I found it in a search a couple years ago but lost the link I had for it.
That's why I thought the paid pump was silly. No private equity is going to invest based on an artificial price.
Everyone should be pleased they were able to raise $5 million at this level. Nemus got $20 million in the same range and they're farther along in their drug development. Getting $5 million indicates they have something of value.
I'll rephrase since you want to cue on semantics rather than sentiment. Schenieder invested $20 million expecting they won't be the only source of future funds and I'm sure they're confident a development deal will get done. As far as the valuation goes, I doubt they think a $10-$15 share price is out of the question without out a split and I'm sure they're in it for the long haul.
Of course they invested with what you call inside information none of us have. There's a proper way to do it that's not illegal and it depends on what is done or not done with the information. Do you think any finance deals, mergers or buyouts would get done without what you call inside information. Companies know who they're dealing with before they lay out all their cards. It goes in stages as the negotiations progress. Schenieder got to see whatever they wanted to see. Don't forget this was a private raise as well.
As far as future valuations, what do you think it will be if just the MRSA drug works?
It was actually closer to 3 million shares. I don't remember if Hollister was involved in the deal but he may have been. It was a deal done through a shell broker and they paid a typical price for a start up biotech at the time. Not ideal but it really is the cheapest and cleanest way to go public if you have limited cash. I think they might have gone a different route if they could have raised more than $2 million when they started 3 years ago. The shell guys always get out as quickly as they can and move on.
That was from a group of traders who came in and did a fly by pump and dump. Everyone who owns this is holding.
I would be surprised if they don't announce a development deal shortly and that is probably what helped in getting $20 million. Schneider signed a non-disclosure and got to see and hear everything. They know more than we know. When you invest that kind of money you have to know that you're not going to be stuck putting more in because you'll be the only source of capital. They must know they're not the only source of capital and that their infusion helps them get a good development deal and the ability to uplist without much dilution. Putting that kind of money in something considered this risky means they're looking for a huge return. 50x plus and they think it's likely.
I don't think they'll be ready for the EB trial until 3rd quarter next year. Anyone have a guess on glaucoma that is behind that?
Theee was literally no volume for the first 6 months. I know the Nemus guys thought it had a $10 valuation so maybe some people got word of that and bought but the stock price dropped when the shell guys started selling their 4 million shares to cash out. Since then it's just been mostly traders.
I've learned more from him than he has from me. He's the smart one.
Even if the FDA changed their stance which I doubt, synthetic is cheaper to manufacture and much easier to achieve required purity standards. Having huge grows to meet drug demand is costly and risky. It's essentially medical marijuana with somewhat higher standards than what's currently available. There isn't much separation and there's a low barrier to entry. I just looked at one of the trials Tetra is doing which is trying to show that their drug can be safely smoked. Are you kidding me? Find me one FDA approved drug where the method of administration is smoking. They have a $100 million market cap? On what? It looks to me like they don't know what they are. Are they a medical marijuana company looking to be able to generate income in the short term without FDA approvals or are they a true biotech? If they're the latter then they are way behind Nemus and if they're wasting money on a drug that can be smoked then I'd run.
Nemus could have used the plant. They could grow all they wanted but they know it's not the future. I'd loosely compare it to heroin vs. the synthetic pain medications. Which one has more purity, more efficient dosing, which one does insurance cover and which one will doctors prescribe?
I don't think they will attempt to uplist until the price is high enough to perhaps not even have to do a split. There's really no hurry now that they have cash. They'll be putting out news that will drive the price including clinical trial results and most likely a development deal. Keep in mind they will probably be able to qualify under the close price exceptions of either $2 or $3 per share and not have to be at $4.
I think GW is the product of the media and being what is perceived as first in. We'll see what that means for them. I think they've floundered trying to figure out how to get there and they've executed as far as shareholders are concerned but the only way I see them being relevant long term is if they acquire a Nemus or someone else. I think they'll have to do acquistions at some point.
The plant is only relevant for research purposes. I think GW is using synthetics for their drugs in clinicals now but haven't paid attention. If they're not then that's a drawback. I thought I read that the FDA will only approve synthetics but they might make an exception for GW for an orphan drug. UofM has taken advantage of their ability to grow by being able to do more research than probably everyone else combined. From that, they have developed a library of IP that can be advanced for commercial purposes. Nemus has started with what they think will bring the most value the fastest. From there, they can keep digging into the vault and keep adding value. That's if it ever gets to that point and Nemus isn't bought out.
Once they get into Phase II, there's going to be a lot of interest from the big guys if not sooner.
GW has been at it for about 20 years so I am a bit amazed that they're not further along. Their path has been with targeted grows and using the plant for their candidates which is kind of puzzling. I think Sativex was doomed because it's orally administered and it contains alcohol which is just nuts. I haven't paid attention to Epidiolex but if I remember correctly, even if it gets approved, it can only be administered for that specific indication. Whereas other drugs that get FDA approval can be administered by doctors however they see fit. It just can't be marketed for anything other than what it was approved for.
Sativex is a spray with a lot of alcohol in it so it can work as a spray. Not well thought out. It's bypassed through the liver.
More reliable delivery. Especially with cannabinoids. Sublingual can be effective but it has to be held under the tongue for a while which can be difficult for people who are really sick. It may be preferred by patients but when you're in bad shape, you need what works and what you can tolerate. They probably expect more definitive results in clinicals with a suppository as well.
Holy cow. That was an amazing synopsis. You should be the PR rep for Nemus. You nailed it.
I really don't have much to add. I do believe Nemus has the most valuable IP of every cannabinoid company in the world. I do believe management is top notch and I know that Nemus' strategy was to choose indications that are the fastest and cheapest to get approval and the easiest to get accurate findings during clinicals. They wanted nothing to do with candidates where the results are subjective like pain. They chose indications that are truly measurable. Nemus had a wealth of choices but they were smart to settle on what they did and they also purposely avoided delivery systems that have to be bypassed through the liver. Everyone reacts and metabolizes oral cannabioinds differently and that's why Marinol is hit and miss and not effective.
The Nemus group which includes the UofM scientists, have believed for years that their leading candidates work. Several years ago I heard their MRSA drug kills it in 2 days. They also don't have to worry about side effects to derail it in trials. That's truly unique and eliminates a huge risk.
They also have some molecular stuff up their sleeve that might hold more value than everything combined. There have been a couple releases alluding to it. And finally, I expect a development deal to come this year.
As far as InMed goes, I don't know what they have but I think their claims are disingenuous. They also recently spent $50k to pump the stock. They claim that their biosynthesis is valuable because they have the best method and everyone is using the plant. Both are completely untrue. Their Bioinformatics isn't anything special in the biotech sphere. They have claimed provisional patents on EB and glaucoma for 2 years but I could never find patent numbers that are issued even for provisionals. I think those releases may have been fake as I got the heads up from someone who would know. They recently made a similar announcement for EB but nothing on where the glaucoma patent stands.
They are talking clinicals for EB next year but they haven't announced that they've even started the process to make the drug. It took Nemus 10 months, which is unusually fast, to make their drug to FDA standards plus 6 months to prove acceptable shelf life so I think InMed is closer to 2 years for trials. Glaucoma is 3 years if that.
Just my quick 2 cents.
I'm not even going to consider selling any of this until it gets to $5 and even then I'm holding the majority. The Nemus guys think this is worth $10 right now but it won't get any analysts covering it until they uplist. They have no retail exposure at all so I'd expect a development deal announcement coming that will bump the price.
The thing about Schneider putting in $20 million, they look at the likelihood of Nemus getting a development deal because they don't want to keep throwing money in and have overexposure. So they must be very confident a deal can get done.
Also, nobody who has participated in the private placement deals is selling.
You're not comprehending. I'm in around .12 and decided to let it all ride up or to nothing. I knew .70-.80 wasn't going to last because of the pump but I'm not in this for a 6x.
If I was so negative I wouldn't have bought in. I'm just a realist. This is an OTC company and they've acted like a typical one at times. If what they claim is true then this will be a huge winner. There are some things I've seen that I like so I'm hopeful. But we have no idea what they really have at this point. We'll have a better idea after the raise.
I'm in this for a home run. Meaning hoping this is legit and goes to $20 plus. All or nothing. I have hope what they're touting is true but I just don't believe they're the only game in town as they claim. It will come down to whether or not what they have has value amongst the competition. Perhaps their Bioinformatics and Biosyntheiss is better or their EB drug is the real deal. I know their glaucoma drug is 2 years behind Nemus but that doesn't mean it's not ultimately better or valuable.
If you're so confident on their press releases, you should put everything you have on this.
Like I said, we'll know what they have with this raise. I'm in hoping there's value here.
The proof if any of this or all of this is true will be if they raise a significant amount of money. To raise that kind of money now would be based on being able to substantiate their Bioinformatics and Biosynthesis IP because they're too far out on their EB and glaucoma candidates to raise more than they have in the past. I'm just hoping that what they've put out there is legit but there are others doing similar things in the lab and nobody other than GW is using the plant. Others are using biosynthesis and computer models. Competitors aren't using primitive methods and InMed will save everyone from that. Hopefully InMed has value in this space but they're not alone as they intimate.
As far as the pump goes, I doubt any serious investor is going to put money in and not consider what the paid pump did to inflate the stock price.
They spent $1 million on research in the last year. Do you have any clue what's included in the admin expenses?
They think it's more effective and a more established way of administering the drug for now. Easier to get fast track approval as well with more reliable results in trials. A lot of the patients who would need this drug are in pretty bad shape so if I remember correctly, they were going by stats that showed the majority of the patients needing this would only be able to tolerate the suppository. I think this is only their short term solution and it will change down the road.
There's limited IP protection unless it's synthetic.
Nemus might be able to skip to Phase II on their chemo drug because of its similarity to Marinol.
Synthetic is what all the big boys are using. Cheaper, easier to manufacture and higher consistent purity. Companies not going the synthetic route are way behind.
New provisional patent question. Anyone know what's the difference between this provisional patent and the one applied for in May 2015? If there's a difference, anyone know the status of the one filed back then?
20 years experience doesn't mean 20 years ahead. Dr. ElSohly has been researching cannabinoids for 45 years but that doesn't mean Nemus is 45 years ahead although they were smart enough to secure patents years ago and made that a priority.
20 years ahead? Maybe 2 or 3. I bought this stock when it hit the penny range taking a shot it could hit. I'm floored the price is this high but I'm not complaining. But I have a realistic vision of what they need to do and having to manufacture their cream in each state in the US or Germany from the plant is not going to generate the revenue for a high valuation. At best, it can help fund clinicals but they have to get FDA approval and equivalent approvals in other countries and develop a synthetic version for this to work. They are 3 years plus away from that if that's the plan.
One of the others I bought is Nemus who collaborates with the University of Mississippi who has researched cannabis for 45 years. They're much further along in synthetic cannabinoid development and has $20 million in cash and a market cap of $8 million which is a joke in comparison to everyone else in the sector.
I own OWCP because the cream potentially can get approval cheaply and quickly and because of potential of early revenue but I'm not delusional enough to think they're going to do more than several million dollars in sales unless they go synthetic and get FDA approval and others across the world.